Cvs Health (CVS) Stock Declined While Gfs Advisors Lowered Its Holding; Ra Capital Management Stake in Sage Therapeutics (SAGE) Decreased by $16.43 Million as Share Value Declined

June 23, 2018 - By Henry Gaston

CVS Health Corporation (NYSE:CVS) Logo

Peter Kolchinsky decreased its stake in Sage Therapeutics Inc (SAGE) by 22.42% based on its latest 2018Q1 regulatory filing with the SEC. Ra Capital Management Llc sold 102,040 shares as the company’s stock declined 7.25% with the market. The hedge fund run by Peter Kolchinsky held 353,133 shares of the health care company at the end of 2018Q1, valued at $56.88M, down from 455,173 at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Sage Therapeutics Inc for a number of months, seems to be less bullish one the $7.14B market cap company. The stock decreased 4.83% or $7.78 during the last trading session, reaching $153.46. About 1.20M shares traded or 106.39% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 127.92% since June 23, 2017 and is uptrending. It has outperformed by 115.35% the S&P500. Some Historical SAGE News: 23/04/2018 – Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression; 18/04/2018 – Sage lntacct and GuideStar Improve Financial Health & Sustainability for Nonprofit Organizations with Innovative Dashboard; 30/05/2018 – Sage Therapeutics: PDUFA Date Set for Dec 19, 2018; 30/05/2018 – SAGE THERAPEUTICS INC – PRIORITY REVIEW STATUS EXPECTED TO ACCELERATE REVIEW PERIOD; PDUFA DATE SET FOR DECEMBER 19, 2018 FOR BREXANOLONE IV; 29/05/2018 – Sage Therapeutics at AllianceBernstein Conference Tomorrow; 22/03/2018 – EPA: EPA Awards Innovative Technology Grants to Cornell University and The Sage Colleges in New York State; 08/05/2018 – Sage Outdoor Adventures Leases Fishing Rights on Piney Valley Ranch; 13/05/2018 – Sage Therapeutics Conference Call Set By Chardan for May. 21; 15/03/2018 – UCSF and Sage Bionetworks Announce Stress Research Study Leveraging New Sensor Technologies on the Samsung Galaxy S9 and S9+; 30/03/2018 – Watercrest Senior Living Group Welcomes Jennifer Lopez as Community Relations Director of Sage Park Assisted Living and Memory

Gfs Advisors Llc decreased its stake in Cvs Health Corp (CVS) by 52.17% based on its latest 2018Q1 regulatory filing with the SEC. Gfs Advisors Llc sold 53,200 shares as the company’s stock declined 3.22% with the market. The institutional investor held 48,778 shares of the medical and nursing services company at the end of 2018Q1, valued at $3.04 million, down from 101,978 at the end of the previous reported quarter. Gfs Advisors Llc who had been investing in Cvs Health Corp for a number of months, seems to be less bullish one the $73.38 billion market cap company. The stock increased 1.55% or $1.1 during the last trading session, reaching $72.18. About 9.11M shares traded or 4.81% up from the average. CVS Health Corporation (NYSE:CVS) has declined 13.06% since June 23, 2017 and is downtrending. It has underperformed by 25.63% the S&P500. Some Historical CVS News: 11/04/2018 – CVS Health to Provide Info, Tools to Choose Lower-Cost Prescription Drugs; 23/04/2018 – Glenview’s Robbins says talk of Amazon’s entering pharma is overblown; 06/03/2018 – S&PGR Downgrades CVS Health To ‘BBB’; Debt Rated ‘BBB’; 21/04/2018 – DJ CVS Health Corporation, Inst Holders, 1Q 2018 (CVS); 04/04/2018 – CVS HEALTH PLANS TO FOCUS ON KIDNEY CARE & DIALYSIS TREATMENT; 11/05/2018 – CVS Health Statement on Trump Administration Initiative to Reduce Drug Costs; 06/03/2018 – S&PGRBulletin: Aetna Rtgs Remain On CW Neg Post CVS Announcmnt; 06/03/2018 – S&PGR Expects CVS Will Pay Down Debt, Resulting in Leverage Improving to Low-4x Area Within One Year of Closing; 13/04/2018 – CVS Health Names Marc-David Munk, MD, MPH, MHCM, as Chief Medical Officer of MinuteClinic and Associate Chief Medical Officer o; 19/04/2018 – CVS Keeps It Real and Unveils Biggest Beauty Campaign Ever

Investors sentiment increased to 0.9 in Q1 2018. Its up 0.18, from 0.72 in 2017Q4. It increased, as 97 investors sold CVS shares while 512 reduced holdings. 117 funds opened positions while 431 raised stakes. 821.03 million shares or 0.67% more from 815.59 million shares in 2017Q4 were reported. Endurant Cap Mngmt Ltd Partnership holds 2.42% or 104,111 shares in its portfolio. Louisiana State Employees Retirement owns 62,000 shares. First Bancshares Sioux Falls invested 0.77% of its portfolio in CVS Health Corporation (NYSE:CVS). Orleans Cap Corporation La owns 0.4% invested in CVS Health Corporation (NYSE:CVS) for 8,675 shares. Loring Wolcott And Coolidge Fiduciary Advsrs Ltd Liability Partnership Ma holds 0.47% in CVS Health Corporation (NYSE:CVS) or 414,012 shares. Moreover, Saturna Capital has 0.02% invested in CVS Health Corporation (NYSE:CVS) for 10,200 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0.25% or 447,764 shares. 433,114 were accumulated by Farr Miller And Washington Lc Dc. 7,835 were reported by Naples Glob Ltd Liability Corp. Moreover, Linscomb Williams Inc has 0.25% invested in CVS Health Corporation (NYSE:CVS). Duncker Streett & has invested 0.62% in CVS Health Corporation (NYSE:CVS). Utd Cap Advisers Ltd Liability Company owns 0.17% invested in CVS Health Corporation (NYSE:CVS) for 357,100 shares. Pennsylvania Trust Company holds 0.24% or 82,674 shares. Smith Moore holds 0.13% in CVS Health Corporation (NYSE:CVS) or 7,954 shares. Van Eck Associate Corp invested 0.17% in CVS Health Corporation (NYSE:CVS).

Since February 16, 2018, it had 2 insider purchases, and 1 sale for $713,454 activity. $1.51M worth of CVS Health Corporation (NYSE:CVS) shares were bought by DORMAN DAVID W. $1.42 million worth of CVS Health Corporation (NYSE:CVS) was sold by Foulkes Helena.

Gfs Advisors Llc, which manages about $755.79M and $483.13 million US Long portfolio, upped its stake in At&T Inc (NYSE:T) by 40,242 shares to 211,041 shares, valued at $7.52 million in 2018Q1, according to the filing. It also increased its holding in Spdr Dow Jones Indl Avrg Etf (DIA) by 3,994 shares in the quarter, for a total of 65,170 shares, and has risen its stake in Apple Inc (NASDAQ:AAPL).

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 77 analyst reports since July 22, 2015 according to SRatingsIntel. The company was maintained on Thursday, January 4 by Robert W. Baird. Robert W. Baird downgraded the stock to “Neutral” rating in Thursday, February 2 report. The stock of CVS Health Corporation (NYSE:CVS) earned “Buy” rating by Leerink Swann on Tuesday, April 10. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, June 20. Morgan Stanley upgraded CVS Health Corporation (NYSE:CVS) on Friday, January 5 to “Overweight” rating. The rating was maintained by Jefferies with “Hold” on Wednesday, October 18. On Wednesday, August 16 the stock rating was maintained by Jefferies with “Hold”. The rating was maintained by Robert W. Baird with “Hold” on Friday, October 27. RBC Capital Markets maintained the shares of CVS in report on Thursday, February 8 with “Buy” rating. The rating was maintained by Loop Capital on Tuesday, November 7 with “Hold”.

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: Nasdaq.com which released: “2 Incredibly Cheap Value Stocks to Buy Now” on June 22, 2018, also Fool.com with their article: “Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today” published on June 19, 2018, Seekingalpha.com published: “CVS And Aetna Are Changing The Healthcare Paradigm” on June 18, 2018. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: 247Wallst.com and their article: “6 Most Important Things in Business Today” published on June 20, 2018 as well as Gurufocus.com‘s news article titled: “CVS Is a Massive Bargain” with publication date: June 22, 2018.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on August, 14. They expect $1.61 EPS, up 21.05% or $0.28 from last year’s $1.33 per share. CVS’s profit will be $1.64B for 11.21 P/E if the $1.61 EPS becomes a reality. After $1.48 actual EPS reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts 8.78% EPS growth.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 earnings per share, up 0.53% or $0.01 from last year’s $-1.88 per share. After $-1.68 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31% negative EPS growth.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Businesswire.com which released: “Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression …” on June 12, 2018, also Businesswire.com with their article: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” published on June 04, 2018, Nasdaq.com published: “Here’s Why Sage Therapeutics Rose as Much as 20.3% Today” on June 12, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Benzinga.com and their article: “Analyst: Sage Therapeutics Holds A Breakthrough In Depression Treatment” published on June 08, 2018 as well as Benzinga.com‘s news article titled: “42 Biggest Movers From Yesterday” with publication date: June 13, 2018.

Among 19 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 17 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 60 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Outperform” on Friday, November 17. The company was maintained on Thursday, February 22 by RBC Capital Markets. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by BMO Capital Markets on Thursday, October 26. The stock has “Buy” rating by Canaccord Genuity on Friday, August 4. SunTrust maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, October 19 with “Buy” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, June 23 by H.C. Wainwright. The stock has “Buy” rating by Leerink Swann on Thursday, September 3. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, November 2. Needham maintained the stock with “Buy” rating in Tuesday, June 13 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by SunTrust on Thursday, December 7.

Investors sentiment increased to 1.73 in 2018 Q1. Its up 0.24, from 1.49 in 2017Q4. It improved, as 22 investors sold SAGE shares while 56 reduced holdings. 47 funds opened positions while 88 raised stakes. 45.19 million shares or 9.02% more from 41.45 million shares in 2017Q4 were reported. Ghost Tree Capital Limited Liability Corporation stated it has 0.36% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Moreover, Amer Century Cos has 0.05% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 322,231 shares. Jacobs Levy Equity Mgmt holds 0.01% or 2,150 shares in its portfolio. Kennedy Cap Mgmt has 0.08% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 27,000 shares. Moreover, Boothbay Fund Management Lc has 0.07% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Invesco holds 0.01% or 145,170 shares in its portfolio. Sectoral Asset Mgmt Inc holds 0.58% or 32,600 shares in its portfolio. Eventide Asset Lc invested in 250,000 shares. Stratos Wealth Ltd stated it has 182 shares. Moreover, Oak Ridge Investments Limited Liability Corporation has 2.5% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Los Angeles Mgmt Equity Inc has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Emerald Advisers Inc Pa stated it has 0.99% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Nj State Employees Deferred Compensation Plan has invested 0.06% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Schwab Charles Investment Mngmt holds 0.03% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 233,945 shares. Kingdon Mgmt Limited Liability Company, New York-based fund reported 35,518 shares.

Since January 10, 2018, it had 0 buys, and 5 sales for $32.85 million activity. IGUCHI KIMI sold $4.02M worth of stock or 28,153 shares. 44,000 Sage Therapeutics, Inc. (NASDAQ:SAGE) shares with value of $7.80M were sold by Kanes Stephen. On Tuesday, March 6 PAUL STEVEN M sold $10.00 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 58,139 shares. $9.96 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by STARR KEVIN P on Tuesday, April 17.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts